Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
547.03
-0.86 (-0.16%)
At close: Nov 11, 2026, 4:00 PM EST
542.94
-4.09 (-0.75%)
After-hours: Nov 11, 2026, 7:51 PM EST

Vertex Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
3,9763,953-535.63,6203,3222,342
Depreciation & Amortization
206.1178.6182169.5148.3125.6
Other Amortization
31.231.225.211.8--
Asset Writedown & Restructuring Costs
-379----
Loss (Gain) From Sale of Investments
----149.1-17.1
Stock-Based Compensation
668.6685.9698.5581.2491.3441.4
Other Operating Activities
-228.6-397.4-347.9-579.1-321.6-143.3
Change in Accounts Receivable
-373.6-347.3-99.3-84.1-358.6-274.7
Change in Inventory
-237-524.2-517.3-322.9-136.4-92.8
Change in Accounts Payable
48.136.849.548.7120.831.9
Change in Other Net Operating Assets
-396.1-364.452.392.6715230.4
Operating Cash Flow
3,6953,631-492.63,5374,1302,644
Operating Cash Flow Growth
-0.63%---14.35%56.23%-18.75%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-492.3-437.6-297.7-200.4-204.7-235
Cash Acquisitions
-9,063----295.9-
Sale (Purchase) of Intangibles
---187.7-58--
Investment in Securities
2,631-483.1-3,231-2,852227.3-105.9
Other Investing Activities
57.8-24.7-54-31-47.8-
Investing Cash Flow
-6,866-945.4-3,770-3,142-321.1-340.9

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----28.3
Total Debt Issued
4,497----28.3
Long-Term Debt Repaid
--5.4-33.6-44.9-85.5-47
Total Debt Repaid
-5.4-5.4-33.6-44.9-85.5-47
Net Debt Issued (Repaid)
4,491-5.4-33.6-44.9-85.5-18.7
Issuance of Common Stock
151.6127.7114.6134.6186.3102
Repurchase of Common Stock
-1,376-2,387-1,582-653.7-172-1,561
Other Financing Activities
-12.73.76.21.83.5-
Financing Cash Flow
3,254-2,261-1,495-562.2-67.7-1,478

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-41.690.9-42.626.9-29.2-13.4
Net Cash Flow
40.8515.6-5,800-139.73,712811.2

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
3,2023,194-790.33,3373,9252,409
Free Cash Flow Growth
-4.04%---14.99%62.97%-19.55%
Free Cash Flow Margin
24.73%26.61%-7.17%33.81%43.95%31.80%
Free Cash Flow Per Share
12.5312.38-3.0612.8115.159.27
Levered Free Cash Flow
2,3382,5732,8003,5103,3072,402
Unlevered Free Cash Flow
2,3662,5812,8193,5383,3422,441

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
12.212.430.543.152.356.3
Cash Income Tax Paid
1,1931,5671,0821,6771,058476.3
Change in Working Capital
-958.6-1,199-514.8-265.7340.8-105.2
SEC Filings: 10-K · 10-Q